A deep learning model for generating [18F]FDG PET Images from early-phase [18F]Florbetapir and [18F]Flutemetamol PET images

被引:0
|
作者
Sanaat, Amirhossein [1 ]
Boccalini, Cecilia [1 ,2 ,3 ]
Mathoux, Gregory [1 ]
Perani, Daniela [4 ]
Frisoni, Giovanni B. [5 ]
Haller, Sven [6 ,7 ]
Montandon, Marie-Louise [8 ,9 ]
Rodriguez, Cristelle [10 ]
Giannakopoulos, Panteleimon [10 ,11 ]
Garibotto, Valentina [1 ,2 ,3 ,12 ]
Zaidi, Habib [1 ,13 ,14 ,15 ]
机构
[1] Geneva Univ Hosp, Div Nucl Med & Mol Imaging, Geneva, Switzerland
[2] Univ Geneva, Geneva Univ Neuroctr, Lab Neuroimaging & Innovat Mol Tracers NIMTlab, Geneva, Switzerland
[3] Univ Geneva, Fac Med, Geneva, Switzerland
[4] Univ Vita Salute San Raffaele, Nucl Med Unit, San Raffaele Hosp, Milan, Italy
[5] Geneva Univ Hosp, Memory Clin, Geneva, Switzerland
[6] CIMC Ctr Imagerie Med Cornavin, Geneva, Switzerland
[7] Univ Geneva, Fac Med, Geneva, Switzerland
[8] Geneva Univ Hosp, Dept Rehabil & Geriatr, Geneva, Switzerland
[9] Univ Geneva, Geneva, Switzerland
[10] Geneva Univ Hosp, Div Inst Measures, Med Direct, Geneva, Switzerland
[11] Univ Geneva, Fac Med, Dept Psychiat, Geneva, Switzerland
[12] CIBM Ctr Biomed Imaging, Geneva, Switzerland
[13] Univ Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands
[14] Univ Southern Denmark, Dept Nucl Med, Odense, Denmark
[15] Obudabuda Univ, Univ Res & Innovat Ctr, Budapest, Hungary
关键词
PET; Neuroimaging; Deep learning; Metabolism; Amyloid; F-18-FDG PET; DIAGNOSIS;
D O I
10.1007/s00259-024-06755-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction Amyloid-beta (A beta) plaques is a significant hallmark of Alzheimer's disease (AD), detectable via amyloid-PET imaging. The Fluorine-(18)-Fluorodeoxyglucose ([F-18]FDG) PET scan tracks cerebral glucose metabolism, correlated with synaptic dysfunction and disease progression and is complementary for AD diagnosis. Dual-scan acquisitions of amyloid PET allows the possibility to use early-phase amyloid-PET as a biomarker for neurodegeneration, proven to have a good correlation to [F-18]FDG PET. The aim of this study was to evaluate the added value of synthesizing the later from the former through deep learning (DL), aiming at reducing the number of PET scans, radiation dose, and discomfort to patients. Methods A total of 166 subjects including cognitively unimpaired individuals (N = 72), subjects with mild cognitive impairment (N = 73) and dementia (N = 21) were included in this study. All underwent T1-weighted MRI, dual-phase amyloid PET scans using either Fluorine-18 Florbetapir ([F-18]FBP) or Fluorine-18 Flutemetamol ([F-18]FMM), and an [F-18]FDG PET scan. Two transformer-based DL models called SwinUNETR were trained separately to synthesize the [F-18]FDG from early phase [F-18]FBP and [F-18]FMM (eFBP/eFMM). A clinical similarity score (1: no similarity to 3: similar) was assessed to compare the imaging information obtained by synthesized [F-18]FDG as well as eFBP/eFMM to actual [F-18]FDG. Quantitative evaluations include region wise correlation and single-subject voxel-wise analyses in comparison with a reference [F-18]FDG PET healthy control database. Dice coefficients were calculated to quantify the whole-brain spatial overlap between hypometabolic ([F-18]FDG PET) and hypoperfused (eFBP/eFMM) binary maps at the single-subject level as well as between [F-18]FDG PET and synthetic [F-18]FDG PET hypometabolic binary maps. Results The clinical evaluation showed that, in comparison to eFBP/eFMM (average of clinical similarity score (CSS) = 1.53), the synthetic [F-18]FDG images are quite similar to the actual [18F]FDG images (average of CSS = 2.7) in terms of preserving clinically relevant uptake patterns. The single-subject voxel-wise analyses showed that at the group level, the Dice scores improved by around 13% and 5% when using the DL approach for eFBP and eFMM, respectively. The correlation analysis results indicated a relatively strong correlation between eFBP/eFMM and [F-18]FDG (eFBP: slope = 0.77, R-2 = 0.61, P-value < 0.0001); eFMM: slope = 0.77, R-2 = 0.61, P-value < 0.0001). This correlation improved for synthetic [F-18]FDG (synthetic [F-18]FDG generated from eFBP (slope = 1.00, R-2 = 0.68, P-value < 0.0001), eFMM (slope = 0.93, R-2 = 0.72, P-value < 0.0001)). Conclusion We proposed a DL model for generating the [F-18]FDG from eFBP/eFMM PET images. This method may be used as an alternative for multiple radiotracer scanning in research and clinical settings allowing to adopt the currently validated [F-18]FDG PET normal reference databases for data analysis.
引用
收藏
页码:3518 / 3531
页数:14
相关论文
共 50 条
  • [21] [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer
    Been, Lukas B.
    Hoekstra, Harald J.
    Suurmeijer, Albert J. H.
    Jager, Pieter L.
    van der Laan, Bernard F. A. M.
    Elsinga, Philip H.
    ORAL ONCOLOGY, 2009, 45 (12) : E211 - E215
  • [22] [18F]-Sodium Fluoride PET and [18F]-FDG PET/CT in prediction of aortic stenosis progression
    Ryzhkova, D. V.
    Kukushkina, S.
    Murtazalieva, P.
    Irtyuga, O.
    Malev, E.
    Moiseeva, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S256 - S257
  • [23] Combined 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy
    Lagaru, A.
    Mittra, E.
    Dick, D.
    Quon, A.
    Goris, M. L.
    Gambhir, S. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S214 - S214
  • [24] Staging with [18F]FDG PET/CT
    Iqbal, Ramsha
    Aras, Tuba
    Mammatas, Lemonitsa
    Vogel, Wouter V.
    Oprea-Lager, Daniela E.
    Verheul, Hendrik M.
    Boellaard, Ronald
    van Oordt, Catharina W. Menke-van der Houven
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Automated PET Quantification of [18F]FDG PET Images for Neurodegenerative Disorders Research
    Cataldo, Sol A.
    Sarmiento Laspiur, Florencia
    Belzunce, Martin A.
    ADVANCES IN BIOENGINEERING AND CLINICAL ENGINEERING, VOL 2, SABI 2023, 2024, 114 : 395 - 403
  • [26] Comparative Analysis between [18F]Fludarabine-PET and [18F]FDG-PET in a Murine Model of Inflammation
    Hovhannisyan, Narinee
    Dhilly, Martine
    Guillouet, Stephane
    Leporrier, Michel
    Barre, Louisa
    MOLECULAR PHARMACEUTICS, 2016, 13 (06) : 2136 - 2139
  • [27] Role of [18F]FDG and [18F]Florbetapir PET/CT to predict Alzheimer's disease development in patients with Down syndrome
    Abouzian, S.
    Valverde, R.
    Pegueroles, J.
    Sizova, M.
    Fuentes, F.
    Fernandez, A.
    Duch, J.
    Lopez-Mora, D.
    Estorch, M.
    Barroeta, I.
    Carmona-Iragui, M.
    Lleo, A.
    Carrio, I.
    Flotats, A.
    Fortea, J.
    Camacho, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S297 - S297
  • [28] [18F]Flutemetamol(Vizamyl)
    周顺光
    宫平
    中国药物化学杂志, 2014, 24 (02) : 167 - 167
  • [29] Biodistribution, pharmacokinetics and PET Imaging of [18F]FMISO, [18F] FDG and [18F]FAc in a sarcoma- and inflammation-bearing mouse model
    Liu, Ren-Shyan
    Chou, Ta-Kai
    Chang, Chih-Hsien
    Wu, Chun-Yi
    Chang, Chi-Wei
    Chang, Tsui-Jung
    Wang, Shih-Jen
    Lin, Wuu-Jyh
    Wang, Hsin-Ell
    NUCLEAR MEDICINE AND BIOLOGY, 2009, 36 (03) : 305 - 312
  • [30] Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for hypoxia PET imaging
    Wack, L. J.
    Moennich, D.
    Van Elmpt, W.
    Zegers, C. M. L.
    Troost, E. G. C.
    Zips, D.
    Thorwarth, D.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S65 - S66